.
IDRA financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
29 833 | 19 900 | 180 893 | 374 378 | 223 278 | 172 256 | 291 186 | 70 493 | 49 097 | 189 059 | 15 974 |
EV * |
5 262 | 9 804 | 154 615 | 355 277 | 197 454 | 92 090 | 178 766 | -938 | 9 241 | 156 021 | 156 021 |
Stock price $ |
8.64 | 5.76 | 32.96 | 36.16 | 15.52 | 10.8 | 14.8 | 2.65 | 1.72 | 5.59 | 0.4723 |
Number of shares * |
3 453 | 3 455 | 5 488 | 10 353 | 14 387 | 15 950 | 19 675 | 26 601 | 28 545 | 33 821 | 33 821 |
EPS |
-6,89 | -5,57 | -3,32 | -3,73 | -3,38 | -2,41 | -3,35 | -2,25 | -1,98 | -3,33 | -3,33 |
Revenue * |
53 | 51 | 47 | 73 | 249 | 16 199 | 902 | 662 | 1 448 | 0 | 0 |
Net income * |
-23 776 | -19 240 | -18 226 | -38 642 | -48 555 | -38 389 | -65 984 | -59 881 | -56 515 | -112 662 | -112 662 |
Operating profit * |
-25 855 | -19 901 | -18 169 | -38 752 | -48 846 | -38 757 | -66 467 | -56 599 | -45 886 | -36 687 | -36 687 |
Total liabilities * |
13 571 | 4 196 | 4 415 | 8 024 | 8 694 | 9 882 | 10 722 | 9 029 | 58 657 | 133 571 | 133 571 |
Net debt * |
-24 571 | -10 096 | -26 278 | -19 101 | -25 824 | -80 166 | -112 420 | -71 431 | -38 957 | -32 280 | -32 280 |
Total assets * |
25 595 | 10 823 | 36 867 | 51 426 | 92 276 | 113 231 | 118 417 | 73 023 | 47 489 | 42 399 | 42 399 |
Equity * |
12 024 | 6 627 | 32 452 | 43 402 | 83 582 | 103 349 | 107 695 | 63 994 | -11 168 | -91 172 | -91 172 |
Cash and investments * |
24 571 | 10 096 | 29 403 | 41 227 | 60 160 | 109 014 | 112 629 | 71 431 | 42 793 | 37 728 | 37 728 |
Over the past 10 years, the maximum capitalization of Idera Pharmaceuticals, Inc. is 374 378, the minimum is 19 900. Maximum net income 0, Minimum net income -112 662. The maximum price of IDRA shares is 36.16, the minimum price is 1.72.
.
IDRA valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1,25 | -1,03 | -9,92 | -9,69 | -4,60 | -4,49 | -4,41 | -1,18 | -0,87 | -1,68 | -0,14 |
P/B |
2,48 | 3,00 | 5,57 | 8,63 | 2,67 | 1,67 | 2,70 | 1,10 | -4,40 | -2,07 | -0,18 |
P/S |
562,88 | 390,20 | 3 848,78 | 5 128,47 | 896,70 | 10,63 | 322,82 | 106,48 | 33,91 | 0,00 | 0,00 |
E/P |
-80% | -97% | -10% | -10% | -22% | -22% | -23% | -85% | -115% | -60% | -705% |
P/FCF |
-1,55 | -1,00 | -10,55 | -11,55 | -5,11 | -6,02 | -5,25 | -1,36 | -1,10 | -5,60 | -0,47 |
.
IDRA profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
-198% | -290% | -56% | -89% | -58% | -37% | -61% | -94% | 506% | 124% | |
ROA |
-93% | -178% | -49% | -75% | -53% | -34% | -56% | -82% | -119% | -266% | |
ROIC |
-133% | -297% | -56% | -87% | -57% | -37% | -61% | -88% | 653% | -104% |